Kanwei Biologic

Kanwei Biologics is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to discovering and developing innovative small molecule therapeutics for metabolic diseases and oncology. The company's lead program, KW-027, is a highly selective thyroid hormone receptor beta (THR-beta) agonist currently in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH/MASH). Kanwei's pipeline also includes candidates targeting the GLP-1 receptor for diabetes and obesity, as well as other metabolic pathways. Founded by industry veterans with deep expertise in medicinal chemistry, the company leverages a robust R&D platform to address significant unmet medical needs in chronic liver and metabolic disorders. Kanwei is backed by prominent venture capital firms, including Qiming Venture Partners and Hillhouse Capital.